There is confusion about the role that IFN-α plays in the pathogenesis of pulmonary arterial hypertension (PAH) with different investigators reporting a causative or a protective role. There is now clear evidence in PAH pathogenesis for the involvement of BMP4 and BMP9 signaling, and its disruption by mutations in BMPR2. In the present study, we investigated MxA, an IFN-α-inducible cytoplasmic dynamin-family GTPase for effects on BMP4/9 signaling, including in the presence of PAH-disease-associated mutants of BMPR2. In human pulmonary arterial endothelial cells (HPAECs), IFN-α-induced endogenous as well as exogenously expressed MxA was associated with endosomes that aligned alongside microtubules and tubules of the endoplasmic reticulum (ER...
Rationale: BMP9 (bone morphogenetic protein 9) is a circulating endothelial quiescence factor with p...
Mutations in the bone morphogenetic protein receptor (BMPR2) gene have been observed in 70 % of pati...
BACKGROUND: Endothelin receptor antagonists improve pulmonary arterial hypertension (PAH). Mutations...
There is confusion about the role that IFN-α plays in the pathogenesis of pulmonary arterial hyperte...
There is confusion about the role that IFN-α plays in the pathogenesis of pulmonary arterial hyperte...
Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) signal...
Background: Bone morphogenetic protein (BMP) signaling has multiple roles in the development and fun...
Pulmonary arterial hypertension (PAH) is a rare disease initiated by dysfunction of the pulmonary va...
<div><h3>Background</h3><p>Bone morphogenetic proteins (BMPs) and their receptors, such as bone morp...
Bone morphogenetic proteins (BMPs) and their receptors, such as bone morphogenetic protein receptor ...
Imbalanced transforming growth factor beta (TGFβ) and bone morphogenetic protein (BMP) signaling are...
Balanced transforming growth factor-beta (TGFβ)/bone morphogenetic protein (BMP)-signaling is essent...
Abstract Background Pulmonary arterial hypertension (PAH) is thought to be driven by dysfunction of ...
Pulmonary arterial hypertension (PAH) is an unmet clinical need. The lack of models of human disease...
RATIONALE: BMP9 (bone morphogenetic protein 9) is a circulating endothelial quiescence factor with p...
Rationale: BMP9 (bone morphogenetic protein 9) is a circulating endothelial quiescence factor with p...
Mutations in the bone morphogenetic protein receptor (BMPR2) gene have been observed in 70 % of pati...
BACKGROUND: Endothelin receptor antagonists improve pulmonary arterial hypertension (PAH). Mutations...
There is confusion about the role that IFN-α plays in the pathogenesis of pulmonary arterial hyperte...
There is confusion about the role that IFN-α plays in the pathogenesis of pulmonary arterial hyperte...
Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) signal...
Background: Bone morphogenetic protein (BMP) signaling has multiple roles in the development and fun...
Pulmonary arterial hypertension (PAH) is a rare disease initiated by dysfunction of the pulmonary va...
<div><h3>Background</h3><p>Bone morphogenetic proteins (BMPs) and their receptors, such as bone morp...
Bone morphogenetic proteins (BMPs) and their receptors, such as bone morphogenetic protein receptor ...
Imbalanced transforming growth factor beta (TGFβ) and bone morphogenetic protein (BMP) signaling are...
Balanced transforming growth factor-beta (TGFβ)/bone morphogenetic protein (BMP)-signaling is essent...
Abstract Background Pulmonary arterial hypertension (PAH) is thought to be driven by dysfunction of ...
Pulmonary arterial hypertension (PAH) is an unmet clinical need. The lack of models of human disease...
RATIONALE: BMP9 (bone morphogenetic protein 9) is a circulating endothelial quiescence factor with p...
Rationale: BMP9 (bone morphogenetic protein 9) is a circulating endothelial quiescence factor with p...
Mutations in the bone morphogenetic protein receptor (BMPR2) gene have been observed in 70 % of pati...
BACKGROUND: Endothelin receptor antagonists improve pulmonary arterial hypertension (PAH). Mutations...